Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-05-17
2005-05-17
MacKenzie, Thomas C. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S247000
Reexamination Certificate
active
06894055
ABSTRACT:
Compounds of formula 1 are effective modulators of PI3 kinase:wherein X is CR9R10, O, NR11(where R9and R10are each independently H, lower alkyl, lower alkoxy, or halo, and R11is H or lower alkyl); or single bond;R1is H, lower alkyl, aryl, aralkyl;R2is H, lower alkyl, aryl, aralkyl, heteroaryl, heteroaryl-alkyl, lower alkoxy, amino, lower alkylamino, lower acylamino, arylamino, arylacyl-amino, heteroaryl-amino, heteroaryl-acyl amino, thio, lower alkylthio, arylthio, or aralkyl-thio, where aryl and heteroaryl are substituted with 0-3 substituents selected from the group consisting of halo, trihalomethyl, hydroxy, lower alkyl and lower alkoxy;R3, R4, R5, R6, R7, and R8are each independently H, lower alkyl, lower alkoxy, or halo;or a pharmaceutically acceptable salt or ester thereof.
REFERENCES:
Arya, V. P., Indian Journal of Chemistry, 10(12), 1141-50 1972.*
Ram, Vishnu J.; Pandey, Hrishi Kesh; Vlietnck, Arnold J., Journal of Heterocyclic Chemistry, 18(7), 1277-80 (English) 1981.*
Wamhoff, Heinrich; Ertas, Muemtaz, Chemiker-Zeitung, 107(11), 344-5 (German) 1983.*
Patil, C.D.; Sadana, G. S.; Deodhar, K.D., Journal of the Indian Chemical Society, 68(3), 169-71 (English) 1991.*
Moneer, A. A.; Ismail, M. Mhsen.; Osman, A. N.; El-Fattah, B. Abd; Ghoneim, K. M., Egyptian Journal of Pharmaceutical Sciences, 1993, 34(4-6), 623-41 (English) 1994.*
Ismail, Khadiga A.; Aboulwafa, Omaima M.; Koreish, Essam, Farmaco, 50(9), 611-16 (English) 1995.*
Oganisyan, A. Sh.; Noravyan, A. S.; Karapetyan, A. A.; Aleksanyan, M. S.;Struchkov, Yu. T., Chemistry of Heterocyclic Compounds, (Translation of Khimiya Geterotsiklicheskikh Soedinenii), 37(5), 628-632 (English) 2001.*
Balla, T., Curr. Pharm. Des., vol. 7(6), 2001, pp. 475-507, Medline abstract 11281854.*
Berrie, C.P., Expert Opin. Investig. Drugs, vol. 10(6), 2001, 1085-1098., Medline abstract 11772237.*
Davies et al., “Specificity and mechanism of action of some commonly used protein kinase inhibitors,”Biochem. J351:95-105, 2000.
Franke et al., “P13K: downstream AKTion blocks apoptosis,”Cell88:435-437, 1997.
Haas-Kogan et al., “Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC,”Curr. Biol. 8:1195-1198, 1998.
Leibel et al., “Radiation therapy for neoplasms of the brain,”J. Neurosurg. 66:1-22, 1987.
Powis et al., “Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase,”Cancer Res. 54:2419-2423, 1994.
Shayesteh et al., “PIK3CA is implicated as an oncogene in ovarian cancer,”Nature Genetics21:99-102, 1999.
Vlahos et al., “A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phemyl-4H-1-benzopyran-4-one (LY294002),”J. Biol. Chem. 269:5241-5248, 1994.
Melese Teri
Nguyen Allen T. Q.
Perkins Edward L.
Sun Dongxu
Howrey Simon Arnold & White , LLP
Iconix Pharmaceuticals Inc.
MacKenzie Thomas C.
Whiting Adam
LandOfFree
Thieno-2′,3′... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thieno-2′,3′..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thieno-2′,3′... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3441166